​

Travere Therapeutics Ownership | Who Owns Travere Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Travere Therapeutics Ownership Summary

Travere Therapeutics is owned by 35.07% institutional investors, 0.74% insiders, and 64.19% retail investors. Blackrock is the largest institutional shareholder, holding 9.86% of TVTX shares. Delaware Small Cap Core I is the top mutual fund, with 4.42% of its assets in Travere Therapeutics shares.

TVTX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockTravere Therapeutics35.07%0.74%64.19%
SectorHealthcare Stocks 42.57%10.84%46.59%
IndustryBiotech Stocks 45.28%10.77%43.95%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock7.64M9.86%$62.84M
Blackrock funding, inc. /de8.10M9.11%$193.60M
Armistice capital6.72M7.56%$160.70M
Vanguard group6.61M7.44%$158.06M
Macquarie group4.98M5.60%$119.13M
Janus henderson group4.06M5.22%$70.69M
Perceptive advisors3.79M4.27%$90.69M
Adage capital partners gp3.55M3.99%$84.89M
State street3.22M3.62%$76.91M
Fmr2.89M3.25%$69.17M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Rock springs capital management lp2.16M3.02%$51.74M
Perceptive advisors3.79M2.62%$90.69M
Knott david m jr260.00K2.51%$6.21M
Armistice capital6.72M2.38%$160.70M
Eversept partners, lp1.42M2.33%$33.87M
Exome asset management156.92K2.27%$3.75M
Kynam capital management, lp949.73K1.69%$22.70M
Emerald advisers2.15M1.64%$51.31M
Emerald mutual fund advisers trust1.20M1.48%$28.70M
Superstring capital management lp53.63K1.26%$1.28M

Top Buyers

HolderShares% AssetsChange
Janus henderson group4.06M0.04%4.03M
Perceptive advisors3.79M2.62%2.96M
Fmr2.89M0.00%1.83M
Stephens investment management group1.60M0.50%1.60M
Wellington management group llp1.20M0.01%1.17M

Top Sellers

HolderShares% AssetsChange
Viking global investors lp---2.60M
Armistice capital6.72M2.38%-2.15M
Finepoint capital lp---1.78M
Assenagon asset management93.36K0.00%-1.01M
Logos global management lp---1.00M

New Positions

HolderShares% AssetsChangeValue
Stephens investment management group1.60M0.50%1.60M$38.23M
Arrowstreet capital, limited partnership328.65K0.01%328.65K$7.85M
Jump financial315.03K0.09%315.03K$7.53M
Neuberger berman group211.67K0.00%211.67K$5.06M
Ikarian capital190.78K0.46%190.78K$4.56M

Sold Out

HolderChange
Twin peaks wealth advisors-1.00
Nelson, van denburg & campbell wealth management group-14.00
American national bank-15.00
Ifp advisors-17.00
Global retirement partners-19.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202597-54.46%31,195,759-67.08%350.31%55-52.17%27-59.09%
Jun 30, 2025221-4.74%100,360,5602.40%1120.92%115-13.53%7120.34%
Mar 31, 202511-94.74%4,535,953-95.23%50.03%5-96.12%3-94.12%
Dec 31, 2024107-42.47%35,070,340-57.58%450.40%66-30.53%23-58.93%
Sep 30, 20241855.11%82,651,760-6.09%1060.82%96-6.80%5414.89%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Delaware Small Cap Core I3.45M4.42%-21.39K
Macquarie Small Cap Core I3.36M3.77%-252.48K
Vanguard Total Stock Mkt Idx Inv2.79M3.13%-61.84K
Aviva Investors GlConvtAbsRet I USD Acc2.20M2.88%-229.35K
Vanguard US Total Market Shares ETF2.51M2.82%-
iShares Russell 2000 ETF2.13M2.39%-
Janus Henderson Global Life Sciences1.76M1.98%510.24K
Janus Henderson Global Life Sciences D1.76M1.98%173.21K
SPDR® S&P Biotech ETF1.51M1.69%3.37K
Janus Henderson Glb Life Scn I2 USD1.50M1.69%53.07K

Recent Insider Transactions

DateNameRoleActivityValue
Jan 20, 2026REED ELIZABETH E Chief Legal Officer and GCSell$273.42K
Jan 06, 2026Inrig Jula CHIEF MEDICAL OFFICERSell$16.80K
Jan 05, 2026Inrig Jula CHIEF MEDICAL OFFICERSell$81.61K
Dec 24, 2025Heerma Peter CHIEF COMMERCIAL OFFICERSell$199.20K
Dec 24, 2025ROTE WILLIAM E. Chief Research OfficerSell$2.41M

Insider Transactions Trends

DateBuySell
2026 Q1-3
2025 Q4-12
2025 Q3-5
2025 Q2-6
2025 Q1-26

TVTX Ownership FAQ

Who Owns Travere Therapeutics?

Travere Therapeutics shareholders are primarily institutional investors at 35.07%, followed by 0.74% insiders and 64.19% retail investors. The average institutional ownership in Travere Therapeutics's industry, Biotech Stocks , is 45.28%, which Travere Therapeutics falls below.

Who owns the most shares of Travere Therapeutics?

Travere Therapeutics’s largest shareholders are Blackrock (7.64M shares, 9.86%), Blackrock funding, inc. /de (8.1M shares, 9.11%), and Armistice capital (6.72M shares, 7.56%). Together, they hold 26.53% of Travere Therapeutics’s total shares outstanding.

Does Blackrock own Travere Therapeutics?

Yes, BlackRock owns 9.86% of Travere Therapeutics, totaling 7.64M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 62.84M$. In the last quarter, BlackRock decreased its holdings by -152K shares, a -1.95% change.

Who is Travere Therapeutics’s biggest shareholder by percentage of total assets invested?

Rock springs capital management lp is Travere Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.02% of its assets in 2.16M Travere Therapeutics shares, valued at 51.74M$.

Who is the top mutual fund holder of Travere Therapeutics shares?

Delaware Small Cap Core I is the top mutual fund holder of Travere Therapeutics shares, with 4.42% of its total shares outstanding invested in 3.45M Travere Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools